Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00153101 · ClinicalTrials.gov registry record · Phase 4
Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 31,546
- Enrollment target
NCT00153101 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 31,546 participants.
The verdict
NCT00153101, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31,546 participants
- Enrollment target
Study Summary
The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of Cardiovascular Death (CV) death, Myocardial infarction (MI), stroke or hospitalization for Congestive Heart Failure (CHF) compared with ramipril 10mg alone; and (b) telmisartan 80mg daily is at least as effective as (i.e. not less effective than) ramipril 10mg daily, on this endpoint. Telmisartan Randomised Assessment Study in Angiotension converting Enzyme inhibitor intolerant subjects with Cardiovascular Disease. (TRANSCEND): The primary objective of the study is to determine if treatment with telmisartan 80mg daily is superior to placebo reducing the composite endpoint of Cardiovascular Death (CV), Myocardial Infarction ( MI)I, stroke or hospitalization for Congestive Heart Failure (CHF) in patients who are intolerant to Angiotension Converting Enzyme inhibitors.
Interventions
- DRUG Ramipril
- DRUG Telmisartan
- DRUG Combination of Telmisartan and Ramipril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31,546 participants |
| Start Date | 2001-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00153101
The ClinicalTrials.gov registry entry for NCT00153101 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 31,546 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ramipril is the first listed.
NCT00153101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00153101 about?
NCT00153101 is a clinical study titled "Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.". The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of Cardiovascular Death (CV) death, ...
What is the current status of trial NCT00153101?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31,546 participants. The study started on 2001-11.
What interventions are being tested in trial NCT00153101?
The interventions under investigation include: Ramipril (DRUG), Telmisartan (DRUG), Combination of Telmisartan and Ramipril (DRUG).
Who is sponsoring clinical trial NCT00153101?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.